Pfizer on April 9 said it will ask U.S. regulators to approve its respiratory syncytial virus (RSV) vaccine for people as young as 18.
The pharmaceutical company said that data from an ongoing phase 3 trial showed the vaccine generated an immune response in people deemed at risk of developing severe illness associated with RSV, similar to the immune response generated in adults aged 65 and up. The vaccine is already approved in the United States for the latter group.
